Does Recombinant Human Activated Protein C (DAA) provide benefit in adults with established and severe septic shock?
Recombinant Human Activated Protein C (DAA) showed no evidence of benefit or harm in adults with established and severe septic shock.
In adults with established and severe septic shock, DAA showed no evidence of benefit or harm. Clinical trial registered with www.clinicaltrials.gov (NCT00625209).
Annane et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: